ALSO NOTED: Genitope's MyVax misses Phase III endpoint; Report: Pfizer looks at Danish biotechs; and much more...

> Genitope's MyVax, a treatment for follicular B-cell non-Hodgkin's lymphoma, has flunked a Phase III trial. There was no difference in progression-free survival between patients taking the drug and the control substance. On the bright side, however, the company noted that the MyVax arm of the trial "showed a highly statistically significant difference in PFS between patients who mounted a positive immune response to the tumor-specific target and those who did not." Genitope's shares took a beating on the news, dropping 50 percent. The company said that it would work with the FDA to determine the best path for MyVax. Release

> Report: According to the site Copenhagen Capacity, Pfizer is taking a close look at several Denmark-based drug developers. A number of Danish biotechs are working on therapies for obesity, diabetes and cancer, all of which may be of interest to Pfizer. Report

> Bavarian Nordic has gained a $25 million milestone payment as part of its deal with the Department of Health and Human Services to provide 20 million doses the smallpox vaccine Imvamune. Release

> The FDA has extended its review of Genta's advanced melanoma treatment Genasense by 60 days. Release

> Daiichi Sankyo will be marching three of its subsidiaries--Sankyo Chemica., Sankyo Organic Chemicals, and Daiichi Sankyo Chemical Pharma--in order to "management resources on the pharmaceutical businesses." Release

> Valeant Pharmaceuticals is selling the U.S. and Canadian rights to Infergen, a hepatitis C treatment. Three Rivers Pharmaceuticals will acquire the drug for $91 million. Valeant says it's selling Infergen in order to simplify its operations. Release

> Redwood City, CA-based A.P. Pharma is on the hunt for a new CEO. Report

And Finally... A group of scientists have derived four embryonic stem cell lines that could lead to the creation of cells that will not cause immune rejection. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.